More than half of patients with metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer will develop brain metastases. Several newly approved HER2-targeted drugs with different mechanisms of action are showing promise in this setting, one of which is able to cross the blood-brain barrier. In this activity, a breast cancer specialist looks at current and emerging HER2-targeted therapies, their mechanisms of action, the clinical trials supporting their benefits in patients with metastatic disease, and best practices for managing treatment-related adverse events.
Interactive, audio-enhanced slide lecture
After completing this activity, participants should be better able to:
- Apply current evidence and guideline recommendations to identify the appropriate use of and optimally sequence HER2-targeted agents in the treatment of HER2-positive metastatic breast cancer
- Evaluate emerging research, the mechanisms of action, and the role of novel HER2-targeted therapies in clinical investigation for patients with HER2-positive metastatic breast cancer
- Implement best practices for the management of HER2-positive breast cancer brain metastases
- Develop strategies to effectively manage adverse events associated with treatments for HER2-positive breast cancer
Oncology NPs, PAs, and nurses
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
The maximum number of hours awarded for this activity is 1.00 contact hours, which includes 1.00 hours of pharmacology credit.
AAPA Credit Designation
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until August 14, 2021. PAs should only claim credit commensurate with the extent of their participation.
This program was developed from a series of programs cosupported by educational grants from Astellas; Astellas and Pfizer; Celgene Corporation; Exelixis; GlaxoSmithKline; Karyopharm Therapeutics; Merck & Co., Inc.; Pharmacyclics LLC, an AbbVie Company; Sanofi Genzyme; Seattle Genetics; and Verastem Oncology.
This activity is supported by an educational grant from Seattle Genetics.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Clinical Care Options, LLC, Practicing Clinicians Exchange, or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Clinical Care Options, LLC are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr McAndrew: advisory board: Genomic Health; advisory board/research funding/speakers bureau: Novartis; advisory board/research funding/travel funding: Daiichi Sankyo; travel funding: Trio Pharmaceuticals, Roche.
Ms Sandy: speakers bureau: AstraZeneca, Merck, Takeda.
None of the members of the Clinical Care Options, LLC staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Watch the eCourse in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
Release date: August 15, 2020
Expiration date: August 14, 2021
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 97520OPCE-7H